Supernus Pharmaceuticals Inc (SUPN)

NASDAQ
29.75
+0.61(+2.08%)
  • Volume:
    392,647
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    29.11 - 30.09

SUPN Overview

Prev. Close
29.15
Day's Range
29.11-30.09
Revenue
564.28M
Open
29.19
52 wk Range
23.15-34.5
EPS
1.51
Volume
392,647
Market Cap
1.59B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
407,607
P/E Ratio
19.33
Beta
1.13
1-Year Change
-2.02%
Shares Outstanding
53,180,768
Next Earnings Date
Mar 01, 2022
What is your sentiment on Supernus Pharmaceuticals Inc?
or
Vote to see community's results!

Supernus Pharmaceuticals Inc Company Profile

Employees
563

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes treatments for epilepsy, migraine, hypomobility in Parkinson’s Disease (PD), cervical dystonia, and chronic sialorrhea. Its commercial portfolio of products includes Trokendi XR (topiramate) and Oxtellar XR (oxcarbazepine) for the treatment of epilepsy. Its APOKYN (apomorphine hydrochloride injection) is a product indicated for the acute, intermittent treatment of hypomobility in patients with advanced parkinson’s disease (PD). Its XADAGO (safinamide) is a product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD. Its MYOBLOC (rimabotulinumtoxinB) is a product indicated for the treatment of cervical dystonia and sialorrhea in adults. Its pipeline of CNS product candidates includes SPN-812, SPN-817, SPN-820, SPN-830 and MYOBLOC.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralBuyBuyBuyStrong Buy
Technical IndicatorsStrong SellNeutralStrong BuySellBuy
SummarySellNeutralStrong BuyNeutralStrong Buy
  • good fundamentals, discount price, solid company. Nice price to add @ 25,20?
    0
    • Josef Kurzmannwhat do you find it was not good in the last report?
      0
    • declining earnings and revenues compared to the prior quarter.
      0
    • i know if the earnings and revenues decline for 1 quarter it isn't a big thing but what will happen if they decline for 2 or 3 quarters, we would possible see $15
      0
  • i sold a couple of days ago, seems like the real market crash is finally coming. I'll re-visit SUPN in a couple of months and decide if the share price fell deep enough.
    3
    • yesterday i sent this stock as an "tip" to some stock advisors and hedge funds (only about 5 combined). the price rose 4.38% and today it is up 3.39% in the pre-market. i will tell more fund managers about this stock and then the price should jump really quick.
      2
      • That moment when Josef thinks he is moving markets 😂
        1
    • one more time:I don't have the knowledge to make an educated guess if the FDA will or will not approve the new ADHD treatment and i am pretty sure you don't have the knowledge and insight eigther.What i know if that SUPN had a great balance sheet, is growing it's revenues 30% per year/earnings 40% per year both since 2016. I also know that their P/E ratio is at 12.5. so i can tell you, even if the new drug doesn't get approved the stock should be at around $90 per share (4.5 billion market cap). Right now it is at $30. If the new drug gets approved it should easily be at $100+ by the end of next year (December 2022) that is a 200%+ return in 23 months.
      1
      • BBRW
        1
    • supernus has a great risk/reward ratio. since 2016 earnings and revenues more than doubled yet the stock price is down 50% ($30 as I'm writing) . revenues and earnings are growing very fast (30%/40%p.a.) and this all makes it very likely that this stock quadrouples over the next 3-5 years.
      1
      • and i didn't even factor in that they have a new revolutionary treatment for ADHD in trial 3 that could be approved by the FDA (then the stock would be worth even more).
        1
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.